Table 2.
Proportion of patients with osteo-metabolic and sarcopenic improvement at T1 assessment, on the basis of the assigned treatment groups.
| Parameter | Overall, N = 40 | Alendronate, N =25 | Denosumab, N =15 | p |
|---|---|---|---|---|
| FN-BMD, N (%) | 23 (57.5) | 16 (64.0) | 7 (46.7) | 0.457 |
| TH-BMD, N (%) | 25 (62.5) | 17 (68.0) | 8 (53.3) | 0.555 |
| LS-BMD, N (%) | 29 (72.5) | 21 (84.0) | 8 (53.3) | 0.082 |
| TBS, N (%) | 15 (37.5) | 12 (48.0) | 3 (20.0) | 0.152 |
| RSMI, N (%) | 18 (45.0) | 10 (40.0) | 8 (53.3) | 0.622 |
| Hand grip, N (%) | 18 (45.0) | 12 (48.0) | 6 (40.0) | 0.870 |
FN, Femoral neck; LS, Lumbar spine; TH, Total hip; BMD, Bone marrow density; TBS, Trabecular bone score; RSMI, Relative skeletal muscle index.